Home » Stocks » GBT

Global Blood Therapeutics, Inc. (GBT)

Stock Price: $28.69 USD -0.75 (-2.55%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
After-hours: $28.88 +0.19 (0.66%) Jul 23, 6:39 PM
Market Cap 1.81B
Revenue (ttm) 148.73M
Net Income (ttm) -249.46M
Shares Out 62.10M
EPS (ttm) -4.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $28.69
Previous Close $29.44
Change ($) -0.75
Change (%) -2.55%
Day's Open 29.58
Day's Range 28.65 - 29.88
Day's Volume 1,160,409
52-Week Range 28.65 - 72.79

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Submits Supplemental New Drug Application to the U.S. FDA for Oxbryta ® (voxelotor) in Children with SCD Ages 4 to 11

2 days ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on July 1, 2021, the compensation committee of GBT's board of dire...

2 weeks ago - GlobeNewsWire

The pharmaceutical company, which specializes in therapies to fight sickle cell disease, rose nearly 8% on Wednesday.

3 weeks ago - The Motley Fool

Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation

1 month ago - GlobeNewsWire

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on June 1, 2021, the compensation committee of GBT's board of dire...

1 month ago - GlobeNewsWire

New Oxbryta® (voxelotor) Data from Phase 2a HOPE-KIDS 1 Study Demonstrate Improvement in Hemoglobin and Hemolysis in Children Ages 4 to 11 Years with Sickle Cell Disease New Oxbryta® (voxelotor) Data fr...

2 months ago - GlobeNewsWire

Global Blood Therapeutics Inc (NASDAQ: GBT) reported a Q1 EPS loss of ($1.21) wider than the anticipated loss estimate of $1.01. Q1 sales of $39.04 million well below the consensus of $43.00 million, al...

2 months ago - Benzinga

The company reported disappointing sales for its sickle-cell disease drug.

2 months ago - The Motley Fool

Global Blood (GBT) reports a wider-than-expected loss in the first quarter of 2021 and its revenues also miss estimates.

2 months ago - Zacks Investment Research

Global Blood (GBT) delivered earnings and revenue surprises of -18.63% and -8.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Achieved Oxbryta ® (voxelotor) net revenues of $39.0 million; on track with plans to potentially expand access to Oxbryta in the U.S. and Europe

2 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif. and HANOVER, Md., May 04, 2021 (GLOBE NEWSWIRE) -- In recognition of World Sickle Cell Day, which falls on June 19, 2021, Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) ...

2 months ago - GlobeNewsWire

Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

With the trading day about halfway over, the broad markets were again somewhat mixed.

Other stocks mentioned: NVCR, TWTR, BRY, CDLX, OGI, SYF, TEAM ...
3 months ago - 24/7 Wall Street

Global Blood Therapeutics Inc (NASDAQ: GBT) has announced The Lancet Haematology has published the complete analysis of 72-week data from the Phase 3 HOPE Study evaluating Oxbryta (voxelotor) tablets in...

3 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced The Lancet Haematology has published the complete analysis of 72-week ...

3 months ago - GlobeNewsWire

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

Global Blood Therapeutics Inc (NASDAQ: GBT) has exclusively in-licensed worldwide rights to two early-stage research programs in sickle cell disease from Sanofi SA (NASDAQ: SNY). One program pursues a n...

Other stocks mentioned: SNY
4 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced it has entered into an agreement with Sanofi S.A. to exclusively in-li...

4 months ago - GlobeNewsWire

Grant proposals from community-based organizations and institutions accepted through April 23, 2021 Grant proposals from community-based organizations and institutions accepted through April 23, 2021

4 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) will participate at the H.C. Wainwright Global Life Sciences Conference on Tuesday, Ma...

4 months ago - GlobeNewsWire

With the trading day more than halfway over, the broad markets saw a huge pull back on Thursday.

Other stocks mentioned: EXPE, MAT, T, URBN, CME, CP, NTAP ...
4 months ago - 24/7 Wall Street

Global Blood (GBT) reports a wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates.

4 months ago - Zacks Investment Research

Global Blood (GBT) delivered earnings and revenue surprises of -3.09% and 6.18%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Shares of Global Blood Therapeutics (NASDAQ:GBT) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 37.11% over the past year to ($1.00...

4 months ago - Benzinga

Achieved Oxbryta ® (voxelotor) net revenues of $41.3 million in the fourth quarter and  $123.8 million for full year 2020

4 months ago - GlobeNewsWire

Global Blood Therapeutics (NASDAQ:GBT) announces its next round of earnings this Wednesday, February 24. Here is Benzinga's everything-that-matters guide for this Wednesday's Q4 earnings announcement.

5 months ago - Benzinga

Global Blood (GBT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2020 financial results...

5 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on February 1, 2021, the compensation committee of GBT's board of ...

5 months ago - GlobeNewsWire

Global Blood's (GBT) Marketing Authorization Application for the label expansion of Oxbryta tablets has been accepted by the European Medicines Agency.

5 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the European Medicines Agency (EMA) has completed the validation o...

5 months ago - GlobeNewsWire

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

Other stocks mentioned: AMPH, AQUA, BBDC, BHVN, CFX, CRHM, HASI ...
5 months ago - Seeking Alpha

Global Blood Therapeutics ended 2020 with a nearly 40% drop in its share price. The pandemic negatively affected the number of Oxbryta prescriptions and therefore Oxbryta sales.

6 months ago - Seeking Alpha

Since 2017, GBT has come a long way to gain Oxbryta approval for treating sickle cell disease. After over 100% capital gains, the stock gave up some profits as the market is sizing up Oxbryta's sales pr...

7 months ago - Seeking Alpha

Two Inclacumab Pivotal Phase 3 Clinical Trials Expected to Begin in F irst H alf of 2021

7 months ago - GlobeNewsWire

Final 72-Week Analyses of Phase 3 HOPE Study Demonstrat e Durable Improvements in Hemoglobin Levels and Significant Improvements in Overall Health Status

7 months ago - GlobeNewsWire

Global Blood (GBT) reported earnings 30 days ago. What's next for the stock?

7 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an early access program for voxelotor, in Europe and ...

7 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that members of the senior management team will participate in virtual ...

7 months ago - GlobeNewsWire

GBT has the only approved drug that can completely reverse sickle cell disease, which is affecting over 250k people worldwide. It has been subjected to an unwarranted selloff due to a slower than expect...

8 months ago - Seeking Alpha

Global Blood Therapeutics (GBT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

8 months ago - Zacks Investment Research

Global Blood Therapeutics (GBT) news for Friday includes poor results from its third-quarter earnings report sending GBT stock lower. The post Global Blood Therapeutics News: 5 Things for GBT Stock Inve...

8 months ago - InvestorPlace

Global Blood (GBT) reports a wider-than-expected loss and misses sales estimates in the third quarter of 2020.

8 months ago - Zacks Investment Research

Global Blood Therapeutics, Inc. (GBT) CEO Ted Love on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Global Blood (GBT) delivered earnings and revenue surprises of -34.72% and -17.26%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Achieved Oxbryta ® (voxelotor) net revenues of $ 36. 9 million with more than 1,000 new patient prescriptions in the third quarter and net revenues of $82.5 million through first nine months of 2020

8 months ago - GlobeNewsWire

Abstracts Include 72-Week Analysis of Phase 3 HOPE Study Supporting  Long-Term Use of Oxbryta ® ( voxelotor )

8 months ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report third quarter 2020 financial results on Thursday, N...

8 months ago - GlobeNewsWire

About GBT

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT6... [Read more...]

Industry
Biotechnology
Founded
2011
CEO
Ted Love
Employees
389
Stock Exchange
NASDAQ
Ticker Symbol
GBT
Full Company Profile

Financial Performance

In 2020, GBT's revenue was $123.80 million, an increase of 5,773.01% compared to the previous year's $2.11 million. Losses were -$247.55 million, -7.20% less than in 2019.

Financial Statements

Analyst Forecasts

According to 20 analysts, the average rating for GBT stock is "Buy." The 12-month stock price forecast is 78.47, which is an increase of 173.51% from the latest price.

Price Target
$78.47
(173.51% upside)
Analyst Consensus: Buy